食品科学 ›› 2026, Vol. 47 ›› Issue (8): 225-239.doi: 10.7506/spkx1002-6630-20250918-142

• 营养卫生 • 上一篇    下一篇

基于肠-肝轴探讨黑果枸杞多糖改善糖尿病合并代谢功能障碍相关脂肪性肝病小鼠的机制

赵耀,谯明,胡君萍,杨建华   

  1. (1.新疆医科大学第一附属医院药学部,新疆 乌鲁木齐 830054;2.新疆医科大学药学院,新疆 乌鲁木齐 830017;3.新疆生物药械重点实验室,新疆 乌鲁木齐 830017;4.新疆药物临床研究重点实验室,新疆 乌鲁木齐 830054)
  • 出版日期:2026-04-25 发布日期:2026-05-15
  • 基金资助:
    新疆科技创新领军人才项目(2024TSYCLJ0048)

Mechanistic Study of Lycium ruthenicum Polysaccharides in Ameliorating Diabetes Complicated by Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice Based on the Gut-Liver Axis

ZHAO Yao, QIAO Ming, HU Junping, YANG Jianhua   

  1. (1. Department of Pharmacy, The First Affiliated Hospital of Xinjiang Medical University, ürümqi 830054, China; 2. College of Pharmacy, Xinjiang Medical University, ürümqi 830017, China; 3. Xinjiang Key Laboratory of Biopharmaceuticals and Medical Devices, ürümqi 830017, China; 4. Xinjiang Key Laboratory of Clinical Drug Research, ürümqi 830054, China)
  • Online:2026-04-25 Published:2026-05-15

摘要: 为探究黑果枸杞多糖(Lycium ruthenicum polysaccharide,LRP)对2型糖尿病合并代谢相关脂肪性肝病(metabolic associated fatty liver disease,MASLD)的改善作用及其作用机制,本研究以db/db小鼠为研究对象,随机分为正常组、模型组以及低、中、高剂量LRP组(50、100、200 mg/kg)和辛伐他汀组(10 mg/kg),干预8 周。结合宏基因组学测序和气相色谱-质谱联用法等技术,评估LRP对小鼠血清生化指标、肝脏组织病理变化、肠道菌群结构以及短链脂肪酸(short chain fatty acids,SCFAs)水平的影响。结果显示,LRP干预可显著降低db/db小鼠血清丙氨酸转氨酶、天冬氨酸转氨酶、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、游离脂肪酸、脂多糖及促炎因子水平,改善小鼠肝脏脂质沉积、炎症浸润及纤维化程度。LRP能够显著改善模型小鼠肠道菌群α多样性,增加有益菌(如Akkermansia muciniphila、Bacteroides acidifaciens)相对丰度,降低条件致病菌(如Klebsiella michiganensis、K. oxytoca)相对丰度,并显著提高粪便乙酸、丙酸、丁酸等SCFAs水平。LRP对肝脏Toll样受体4/NOD样受体热蛋白结构域相关蛋白3/核因子κB(Toll-like receptor 4/NOD-like receptor pyrin domain-containing 3/nuclear factor-κB,TLR4/NLRP3/NF-κB)炎症信号通路具有抑制作用,能下调TLR4、髓样分化因子88、NLRP3、半胱天冬酶-1(Caspase-1)、白细胞介素-1β蛋白表达,以及降低NF-κB磷酸化水平。综上,LRP对2型糖尿病合并MASLD具有显著的改善作用,其机制可能通过调控肠道菌群结构、提高SCFAs产生、抑制肝脏炎症信号通路实现,本研究可为开发黑果枸杞功能性食品提供理论依据。

关键词: 黑果枸杞多糖;2型糖尿病;代谢相关脂肪性肝病;肠道菌群;短链脂肪酸;Toll样受体4/NOD样受体热蛋白结构域相关蛋白3/核因子κB信号通路

Abstract: This study aimed to investigate the ameliorative effects of Lycium ruthenicum polysaccharides (LRP) on type 2 diabetes mellitus (T2DM) complicated by metabolic dysfunction-associated steatotic liver disease (MASLD) and to elucidate its underlying mechanisms. db/db mice were randomly divided into six groups: control, model, low-, medium-, and high-dose LRP (50, 100, and 200 mg/kg), and simvastatin (10 mg/kg). The intervention period lasted for eight weeks. Metagenomic sequencing and gas chromatography-mass spectrometry (GC-MS) were used to evaluate the effect of LRP on serum biochemical parameters, hepatic histopathology, gut microbiota structure, and short-chain fatty acid (SCFA) profiles in mice. LRP treatment significantly reduced serum alanine aminotransferase, aspartate aminotransferase, total cholesterol, triglycerides, low-density lipoprotein cholesterol, free fatty acids, lipopolysaccharide, and pro-inflammatory cytokine levels, while alleviating hepatic lipid accumulation, inflammation, and fibrosis. Moreover, LRP enhanced the α-diversity of the gut microbiota, increased the relative abundance of beneficial bacteria such as Akkermansia muciniphila and Bacteroides acidifaciens, and decreased that of conditional pathogenic bacteria such as Klebsiella michiganensis and K. oxytoca. LRP also elevated fecal SCFA concentrations (acetate, propionate, and butyrate) and suppressed the hepatic Toll-like receptor 4/NOD-like receptor pyrin domain-containing 3/nuclear factor-κB (TLR4/NLRP3/NF-κB) signaling pathway by downregulating the expression of TLR4, MyD88, NLRP3, caspase-1, and interleukin-1β (IL-1β) and thereby reducing NF-κB phosphorylation. In conclusion, LRP exerts potent protective effects against T2DM-associated MASLD by restoring gut microbiota homeostasis, enhancing SCFA production, and inhibiting the hepatic inflammatory signaling pathway. This finding provides a scientific rationale for developing L. ruthenicum-based functional food products.

Key words: Lycium ruthenicum polysaccharides; type 2 diabetes mellitus; metabolic associated fatty liver disease; gut microbiota; short chain fatty acids; Toll-like receptor 4/NOD-like receptor pyrin domain-containing 3/nuclear factor-κB signaling pathway

中图分类号: